N

Noile-Immune Biotech Inc
TSE:4893

Watchlist Manager
Noile-Immune Biotech Inc
TSE:4893
Watchlist
Price: 188 JPY -6.93% Market Closed
Market Cap: 8.1B JPY

Noile-Immune Biotech Inc
Free Cash Flow

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Noile-Immune Biotech Inc
Free Cash Flow Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Free Cash Flow CAGR 3Y CAGR 5Y CAGR 10Y
N
Noile-Immune Biotech Inc
TSE:4893
Free Cash Flow
-ÂĄ873.1m
CAGR 3-Years
-43%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
GNI Group Ltd
TSE:2160
Free Cash Flow
-ÂĄ1.5B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-3%
PeptiDream Inc
TSE:4587
Free Cash Flow
ÂĄ25.1B
CAGR 3-Years
69%
CAGR 5-Years
48%
CAGR 10-Years
80%
Takara Bio Inc
TSE:4974
Free Cash Flow
ÂĄ3.2B
CAGR 3-Years
-32%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Pharma Foods International Co Ltd
TSE:2929
Free Cash Flow
ÂĄ4.5B
CAGR 3-Years
-8%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
C
Cuorips Inc
TSE:4894
Free Cash Flow
-ÂĄ487m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A

Noile-Immune Biotech Inc
Glance View

Market Cap
8.1B JPY
Industry
Biotechnology

Noile-Immune Biotech, Inc. engages in the development of CAR-T cell therapy, a cancer immunotherapy for solid tumors using proprietary technology. The company is headquartered in Minato-Ku, Tokyo-To. The company went IPO on 2023-06-28. The Cancer Immunotherapy Drug Discovery Business segment develops various gene-modified immuno-cell therapies for the treatment of solid tumors, mainly by combining PRIME technology, a platform technology, with therapeutic technologies targeting various antigens expressed by solid tumors. The firm establishes a hybrid business model with two business models: in-house drug discovery, in which the company takes the initiative in drug discovery, and joint pipeline, in which PRIME technology is licensed to other companies for drug development.

Noile-Immune Biotech Inc Intrinsic Value
HIDDEN
Show

See Also

What is Noile-Immune Biotech Inc's Free Cash Flow?
Free Cash Flow
-873.1m JPY

Based on the financial report for Dec 31, 2023, Noile-Immune Biotech Inc's Free Cash Flow amounts to -873.1m JPY.

What is Noile-Immune Biotech Inc's Free Cash Flow growth rate?
Free Cash Flow CAGR 3Y
-43%

Over the last year, the Free Cash Flow growth was -715%. The average annual Free Cash Flow growth rates for Noile-Immune Biotech Inc have been -43% over the past three years .

Back to Top